A rare case of late-onset limb-girdle muscular dystrophy: Calpainopathy

Bhawana Painkra1 | Richa Mallick1 | Sumanta Das2 | Pramod Kumar1 | Prasun Chatterjee1

1Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India
2Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

Correspondence
Pramod Kumar, Department of Geriatric medicine, All India Institute of Medical Sciences, 3095-A, 3rd Floor, Academic Block, New Delhi, India.
Email: pramodatalims.001@gmail.com

1 | INTRODUCTION

Calpainopathy is the most common limb-girdle muscular dystrophy subtype (40%) worldwide.1 Its usual presentation is in patients between 5 and 20 years of age (75% of cases).2 Here, we present a case of late-onset calpainopathy presenting at an age of 65 years, which is extremely rare and has been previously described only in a couple of case reports.3–5

2 | CASE PRESENTATION

A 65-year-old man, presented with a history of bilateral, proximal lower limb weakness for the past 1 year. It started with difficulty in climbing upstairs and gradually progressed such that he required support for walking on level ground. He also developed difficulty turning from side to side and proximal muscle weakness in bilateral arms for the last 8 months. He also complained of occasional muscle cramps, although he had no associated tenderness, stiffness, or joint pain. Distal muscle, and sensory and cranial nerve involvement were absent and there was no fever or weight loss history. He had a history of pulmonary tuberculosis, but no other comorbidities. There was no similar illness in the family members.

On examination, there was hypertrophy of calf muscles in both the lower limbs and bilaterally symmetrical winging of the scapula (Figure 1). Power was reduced bilaterally, around the shoulder joints (4/5) and hip joints (4/5) in all ranges of motion, as well as the trunk muscle (3/5). Beevor’s sign was absent. Deep tendon reflexes, sensory examination, and cranial nerve examination were normal. There was a lordotic posture and a waddling, broad-based gait. The rest of the systems were normal on examination.

Blood investigations showed only mildly raised creatine kinase (CK) levels (Table 1). Electromyography was suggestive of a "myopathic pattern." Polyphasic MUAPs with short duration and small amplitude were seen in the right biceps and right vastus lateralis.

The patient underwent a muscle biopsy from the right vastus lateralis muscle. Histopathology showed loss of fascicular architecture and variation in fiber size, with few regenerating and degenerating fibers. There was perimysial and endomysial adipose tissue infiltration (Figure 2). NADHTR revealed few lobulated fibers (Figure 3). Immunohistochemistry showed normal staining patterns for alpha, beta, and gamma sarcoglycan and dysferlin. Immunoblot was suggestive of an absent calpain band, suggesting calpainopathy as a likely diagnosis (Figure 4).

Thus, based on clinical, electromyogram, and histopathology reports, a diagnosis of late-onset calpainopathy was made.

The patient was prescribed muscle strengthening exercises, namely high sitting-hip flexion, adductor squeeze with knee flexion and extension, static and dynamic quadriceps, side-lying shoulder exercises, and scapular protraction and retraction. He was discharged with a home exercise program. On follow-up after 6 weeks, he reported improvement in the symptoms.

3 | DISCUSSION

Calpainopathies are of two types: LGMD R1, calpain-3-related (previously LGMD2A) is an autosomal recessive disease and LGMD D4, was an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.
**FIGURE 1** Calf muscle hypertrophy (A) and winging of the scapula (B)

**TABLE 1** Laboratory parameters

| Tests                              | Values          | Normal range | Remarks |
|------------------------------------|-----------------|--------------|---------|
| Hemoglobin                         | 13.7 g/dl       | 12–15        | WNL     |
| Total leukocyte counts             | 6590/cu mm      | 4000–11,000  | WNL     |
| Differential leukocyte counts (N/L/M/E) | 58.8/29.4/5.9/0.6 | N-40–80      | WNL     |
| Platelets                          | 216,000μl       | 150,000–400,000 | WNL     |
| Hematocrit                         | 44.0%           | 36–46        | WNL     |
| Urea                               | 13 mg/dl        | 17–49        | WNL     |
| Creatinine                         | 0.4 mg/dl       | 0.5–0.9      | WNL     |
| Uric acid                          | 4.1 mg/dl       | 2.4–5.7      | WNL     |
| Calcium                            | 8.0 mg/dl       | 8.6–10.0     | WNL     |
| Phosphorus                         | 2.8 mg/dl       | 2.5–4.5      | WNL     |
| Sodium                             | 141 mmol/L      | 135–145      | WNL     |
| Potassium                          | 4.8 mmol/L      | 3.5–5.1      | WNL     |
| Erythrocyte sedimentation rate     | 22 mm / h       | <32          | WNL     |
| C-reactive protein                 | < 0.5           |              | WNL     |
| Aspartate aminotransferase         | 29 U/L          | ≤32          | WNL     |
| Alanine aminotransferase           | 44 U/L          | ≤33          | WNL     |
| Total protein                      | 8.0 g/dl        | 6.4–8.3      | WNL     |
| Total bilirubin                    | 0.91 mg/dl      | 0–1.2        | WNL     |
| Alkaline phosphatase               | 64 mg/dl        | 35–104       | WNL     |
| Albumin                            | 4.7 g/dl        | 4.0–4.9      | WNL     |
| HbA1c                              | 5.6%            |              | WNL     |
|                                    |                 | Non-diabetic range: 4.8–5.6 Prediabetic range: 5.7%–6.4% Diabetes range: ≥6.5% High risk: >7.0% |
| Creatine kinase                    | 600U/L          | 39–308       | Raised  |
| Vitamin D                          | 22.8 U/L        | 10–44        | WNL     |
| iPTH                               | 18.2 pg/ml      | 15–65        | WNL     |
| TSH                                | 3.20μIU/ml      | 0.27–4.20    | WNL     |
| T3                                 | 72 ng/dl        | 80–200       | WNL     |
| T4                                 | 7.4 μg/dl       | 5.1–14.1     | WNL     |
| Sr Cortisol                        | 8 mcg/dl        | (5–23)       | WNL     |
| Myositis profile                   | Negative        |              |         |
| ANA, ANCA, RF                      | Negative        |              |         |

Abbreviation: WNL, within normal limits.
Calpain-3, a calcium-dependent cysteine protease, helps regulate calcium outflow from the sarcoplasmic reticulum, interacts with cytoskeletal proteins, such as titin and dysferlin, and plays an important role in sarcomere assembly, remodeling, and repair.\(^6,7\) Possibly, loss-of-function pathogenic calpain-3 variants lead to recessive disease with abnormal muscle sarcomeres and eventual muscle fibers death.\(^8\) The autosomal dominant disease is due to certain single pathogenic \textit{CAPN3} variants that exert a dominant-negative deleterious effect on protein function.\(^9\)

Autosomal recessive calpainopathy (LGMD R1) is considered the most common type of LGMD worldwide,\(^10\) with variation depending in part on the geographic region.\(^8,11\) The phenotype is variable, ranging from pelvic and shoulder girdle muscle weakness to asymptomatic disease with elevated serum CK levels (hyperCKemia).\(^8\) The severe disease significantly involves the parascapular muscles, biceps, gluteus maximus, adductors, and hamstrings. Hip girdle muscles are weaker than shoulder girdle muscles, with severe weakness involving hip extension, adduction, and knee flexion. Scapular winging, abdominal laxity, hyperlordosis, and a waddling gait are common, as was observed in our patient. Contractures are extensive and tend to develop early. Facial weakness may occur in cases with early-onset or severe disease.\(^8\) CK levels range from 500 to 20,000 units/L. In our patient, the CK level was 600 units/L. Muscle biopsy often shows lobulated fibers, as seen in our case. Cardiac and pulmonary involvement is unusual.\(^7\)
Although course and severity are variable, the requirement for a wheelchair occurs between the ages of 21 and 40 years in ~80%. The autosomal dominant calpainopathy (LGMD D4) has a phenotype that resembles but is generally milder than the recessive form. As an extremely rare presentation, the patient in this case report had an onset of weakness above 60 years of age and was walking independently with minimal support at an age of 65 years. Single-gene genetic diseases are now being reported in elderly patients more often. Some of the possible explanations for this phenomenon can be the overall increasing lifespan, increasing awareness about such disease entities, and the recent advent of DNA-based genetic testing. Our patient denied genetic analysis, and a probable diagnosis of calpainopathy was made based on biopsy and immunoblot reports.

The role of exercise in limb-girdle muscular dystrophy has been reported in previous studies which showed improvement after exercise. The above patient also showed a good response to physiotherapy.

In conclusion, older adults may rarely present with genetic disorders which have the usual age of onset at a young age, and such diagnoses should not be dismissed merely based on the age of the patient. A high index of suspicion and systematic approach may help to make such rare diagnoses and provide optimum therapy.

AUTHOR CONTRIBUTIONS
Bhawana Painkra, Richa Mallick, Pramod Kumar, and Prasun Chatterjee were directly involved in patient evaluation and management; and case report manuscript planning, writing and review. Sumanta Das was involved in evaluation and reporting of biopsy slides.

ACKNOWLEDGMENTS
The authors would like to thank the Department of Neurology, AIIMS New Delhi Physiotherapy Team, Department of Geriatric Medicine, AIIMS New Delhi.

CONFLICT OF INTEREST
Nothing to disclose.

INFORMED CONSENT
Written informed consent was taken from the patient.

REFERENCES
1. Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG. Limb-girdle muscular dystrophy in the Agarwals: utility of founder mutations in CAPN3 gene. Ann Indian Acad Neurol. 2016;19(1):108-111. doi:10.4103/0972-2327.175435
2. Calpainopathy – GeneReviews® – NCBI Bookshelf. Accessed April 29, 2022. https://www.ncbi.nlm.nih.gov/books/NBK1313/
3. Hofmeister F, Baber L, Ferrari U, et al. Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia. BMC Neurol. 2021;21(1):241. doi:10.1186/s12883-021-02264-y
4. Bird TD, Lipe HP, Steinbart EJ. Geriatric neurogenetics: oxymoron or reality? Arch Neurol. 2008;65(4):537-539. doi:10.1001/archneur.65.4.537
5. Furuta M, Sumi-Akamaru H, Takahashi MP, Hayashi YK, Nishino I, Mochizuki H. An elderly-onset limb girdle muscular dystrophy type 1B (LGMD1B) with pseudo-hypertrophy of paraspinal muscles. Neuromuscul Disord. 2016;26(9):593-597. doi:10.1016/j.nmd.2016.05.002
6. Wicklund MP, Kissel JT. The limb-girdle muscular dystrophies. Neurol Clin. 2014;32(3):729-749. doi:10.1016/j.ncl.2014.04.005
7. Gallardo E, Saenz A, Illa I. Limb-girdle muscular dystrophy 2A. Handb Clin Neurol. 2011;101:97-110. doi:10.1016/B978-0-08-045031-5.00006-2
8. Angelini C, Fanin M. Calpainopathy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®, University of Washington; 1993. Accessed April 29, 2022. http://www.ncbi.nlm.nih.gov/books/NBK1313/
9. Vissing J, Barresi R, Witting N, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain J Neurol. 2016;139(Pt 8):2154-2163. doi:10.1093/brain/aww133
10. Wicklund MP, Hilton-Jones D. The limb-girdle muscular dystrophies: genetic and phenotypic definition of a disputed entity. Neurology. 2003;60(8):1230-1231. doi:10.1212/wnl.60.8.1230
11. Bushby KMD, Beckmann JS. The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12-14, 2002. Neuromuscul Disord. 2003;13(1):80-90. doi:10.1016/s0960-8966(02)00183-9
12. Medline® Abstract for Reference 16 of “Limb-girdle muscular dystrophy” – UpToDate. Accessed May 5, 2022. https://www.uptodate.com/contents/limb-girdle-muscular-dystrophy/abstract/16
13. Jensen BR, Berthelsen MP, Husu E, Christensen SB, Prahm KP, Vissing J. Body weight-supported training in Becker and limb girdle 2I muscular dystrophy. Muscle Nerve. 2016;54(2):239-243. doi:10.1002/mus.25039
14. Bajpai A. Physiotherapy in calpainopathy (LGMD2A): a case report. Clin Case Rep Int. 2020;4(1):1158-1159. Accessed July 4, 2022. http://mail.remedypublications.com/clinical-case-reports-inter nationalabstract

How to cite this article: Painkra B, Mallick R, Das S, Kumar P, Chatterjee P. A rare case of late-onset limb-girdle muscular dystrophy: Calpainopathy. Aging Med. 2022;5:237-240. doi:10.1002/agm2.12219